Brief: Fate Therapeutics Reports First Quarter 2023 Financial Results And Business Updates

Fate Therapeutics

03/05/2023 21:41

May 3 (Reuters) - Fate Therapeutics Inc  FATE.O :
    * FATE THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND BUSINESS UPDATES
    * DOSE ESCALATION ONGOING IN LANDMARK PHASE 1 STUDY OF FT819
CD19-TARGETED 1XX CAR T-CELL PROGRAM
    * CLINICAL INITIATION OF FT522 ADR-ARMED, CD19-TARGETED CAR
NK
CELL PROGRAM FOR B-CELL LYMPHOMA ANTICIPATED IN 2H23
    * COMPLETED CORPORATE RESTRUCTURING AND STRATEGIC ASSESSMENT
OF
PIPELINE ASSETS
    * ENDED Q1 WITH $426 MILLION IN CASH, CASH EQUIVALENTS, AND
RECEIVABLES SUPPORTING RUNWAY INTO H2 2025
    * QTRLY LOSS PER SHARE $0.19
    * Q1 EARNINGS PER SHARE VIEW $-0.62 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX8JyGgl 
Further company coverage:  FATE.O 

 ((Reuters.Briefs@thomsonreuters.com;))